Overexpression of long non‑coding RNA n346372 in bladder cancer tissues is associated with a poor prognosis

Liu,Anwei; Zhang,Zhensheng; Xu,Weidong; Qin,Shengfei; Hua,Meimian; Zeng,Shuxiong; Xu,Chuanliang

doi:10.3892/mmr.2018.9597

Overexpression of long non‑coding RNA n346372 in bladder cancer tissues is associated with a poor prognosis

Authors:
- Anwei Liu
- Zhensheng Zhang
- Weidong Xu
- Shengfei Qin
- Meimian Hua
- Shuxiong Zeng
- Chuanliang Xu
View Affiliations

Affiliations: Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China
Published online on: October 25, 2018 https://doi.org/10.3892/mmr.2018.9597
Pages: 5437-5444
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accumulating evidence has confirmed that dysregulated long non‑coding RNAs (lncRNAs) participate in the initiation and progression of a number of solid tumors and have potential applications for early diagnosis, targeted therapy, and the prognosis of patients with bladder cancer. In the present study, via high‑throughput sequencing technology and bioinformatics analysis, a total of 169 lncRNAs with significantly differential expression between bladder cancer tissues and paired adjacent normal tissues (n=10) were initially identified by screening. Reverse‑transcription‑quantitative polymerase chain reaction was carried out to validate the expression levels of lncRNA‑n346372 in 60 pairs of tissue samples from bladder cancer patients. The results indicated that lncRNA‑n346372 was upregulated in bladder cancer tissues compared with the matched adjacent normal tissues (P<0.05). In addition, the results of fluorescence in situ hybridization analysis of bladder cancer cells and tissues demonstrated that lncRNA‑n346372 is located in the cytoplasm, and the expression of lncRNA‑n346372 in bladder cancer tissues was significantly increased compared with the paired normal tissues. Following a χ2 test with common clinical variables among the patients, the expression level of lncRNA‑n346372 was demonstrated to be positively associated with advanced tumor stage and poor histological differentiation of bladder cancer. Kaplan‑Meier survival analysis revealed that patients with high expression of n346372 were more likely to have a poor prognosis compared with patients with low n346372 expression. Finally, univariate and multivariate analyses indicated that the relative level of n346372, apart from tumor stage and histological grade, may serve as an independent prognostic factor of bladder cancer. To the best of the authors' knowledge, this is the first study to verify the dysregulated expression of lncRNA‑n346372 in bladder cancer; an association of this lncRNA with overall survival of bladder cancer patients was also uncovered in the present study, suggesting that lncRNA‑n346372 may contribute to the initiation and/or progression of bladder cancer with potential applications in the clinic.

View Figures

View References

1	Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
2	Witjes JA, Compérat E, Cowan NC, De Santis M, Gakis G, Lebret T, Ribal MJ, Van der Heijden AG and Sherif A: European Association of Urology: EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. Eur Urol. 65:778–792. 2014. View Article : Google Scholar : PubMed/NCBI
3	Chen J, Wang L, Tang Y, Gong G, Liu L, Chen M, Chen Z, Cui Y, Li C, Cheng X, et al: Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy. J Exp Clin Cancer Res. 35:22016. View Article : Google Scholar : PubMed/NCBI
4	Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et al: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 515:558–562. 2014. View Article : Google Scholar : PubMed/NCBI
5	Alfred WJ, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, Hernández V, Espinós EL, Dunn J, Rouanne M, et al: Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 71:462–475. 2017. View Article : Google Scholar : PubMed/NCBI
6	Mohammed AA, El-Tanni H, El-Khatib HM, Mirza AA, Mirza AA and Alturaifi TH: Urinary bladder cancer: biomarkers and target therapy, new era for more attention. Oncol Rev. 10:3202016. View Article : Google Scholar : PubMed/NCBI
7	Chen T, Xie W, Xie L, Sun Y, Zhang Y, Shen Z, Sha N, Xu H, Wu Z, Hu H and Wu C: Expression of long noncoding RNA lncRNA-n336928 is correlated with tumor stage and grade and overall survival in bladder cancer. Biochem Biophys Res Commun. 468:666–670. 2015. View Article : Google Scholar : PubMed/NCBI
8	Necsulea A, Soumillon M, Warnefors M, Liechti A, Daish T, Zeller U, Baker JC, Grützner F and Kaessmann H: The evolution of lncRNA repertoires and expression patterns in tetrapods. Nature. 505:635–640. 2014. View Article : Google Scholar : PubMed/NCBI
9	Zhang M, Lu W, Huang Y, Shi J, Wu X, Zhang X, Jiang R, Cai Z and Wu S: Downregulation of the long noncoding RNA TUG1 inhibits the proliferation, migration, invasion and promotes apoptosis of renal cell carcinoma. J Mol Histol. 47:421–428. 2016. View Article : Google Scholar : PubMed/NCBI
10	Zhang Q, Su M, Lu G and Wang J: The complexity of bladder cancer: Long noncoding RNAs are on the stage. Mol Cancer. 12:1012013. View Article : Google Scholar : PubMed/NCBI
11	Pan J, Li X, Wu W, Xue M, Hou H, Zhai W and Chen W: Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer Lett. 382:64–76. 2016. View Article : Google Scholar : PubMed/NCBI
12	Ying L, Huang Y, Chen H, Wang Y, Xia L, Chen Y, Liu Y and Qiu F: Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. Mol Biosyst. 9:407–411. 2013. View Article : Google Scholar : PubMed/NCBI
13	Hua Q, Lv X, Gu X, Chen Y, Chu H, Du M, Gong W, Wang M and Zhang Z: Genetic variants in lncRNA H19 are associated with the risk of bladder cancer in a Chinese population. Mutagenesis. 31:531–538. 2016. View Article : Google Scholar : PubMed/NCBI
14	Yang C, Li X, Wang Y, Zhao L and Chen W: Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells. Gene. 496:8–16. 2012. View Article : Google Scholar : PubMed/NCBI
15	Wang Y, Chen W, Yang C, Wu W, Wu S, Qin X and Li X: Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol. 41:276–284. 2012.PubMed/NCBI
16	Zhan Y, Lin J, Liu Y, Chen M, Chen X, Zhuang C, Liu L, Xu W, Chen Z, He A, et al: Up-regulation of long non-coding RNA PANDAR is associated with poor prognosis and promotes tumorigenesis in bladder cancer. J Exp Clin Cancer Res. 35:832016. View Article : Google Scholar : PubMed/NCBI
17	Zhan Y, Li Y, Guan B, Chen X, Chen Z, He A, He S, Gong Y, Peng D, Liu Y, et al: Increased expression of long non-coding RNA CCEPR is associated with poor prognosis and promotes tumorigenesis in urothelial bladder carcinoma. Oncotarget. 8:44326–44334. 2017. View Article : Google Scholar : PubMed/NCBI
18	Hayn MH, Hussain A, Mansour AM, Andrews PE, Carpentier P, Castle E, Dasgupta P, Rimington P, Thomas R, Khan S, et al: The learning curve of robot-assisted radical cystectomy: Results from the International Robotic Cystectomy Consortium. Eur Urol. 58:197–202. 2010. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Gibb EA, Brown CJ and Lam WL: The functional role of long non-coding RNA in human carcinomas. Mol Cancer. 10:382011. View Article : Google Scholar : PubMed/NCBI
21	Struhl K: Transcriptional noise and the fidelity of initiation by RNA polymerase II. Nat Struct Mol Biol. 14:103–105. 2007. View Article : Google Scholar : PubMed/NCBI
22	Gupta Chandra S and Tripathi Nandan Y: Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. Int J Cancer. 140:1955–1967. 2017. View Article : Google Scholar : PubMed/NCBI
23	Mercer TR, Dinger ME and Mattick JS: Long non-coding RNAs: Insights into functions. Nat Rev Genet. 10:155–159. 2009. View Article : Google Scholar : PubMed/NCBI
24	Harries LW: Long non-coding RNAs and human disease. Biochem Soc Trans. 40:902–906. 2012. View Article : Google Scholar : PubMed/NCBI
25	Zhou M, Zhao H, Wang Z, Cheng L, Yang L, Shi H, Yang H and Sun J: Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma. J Exp Clin Cancer Res. 34:1022015. View Article : Google Scholar : PubMed/NCBI
26	Zhang Q, Su M, Lu G and Wang J: The complexity of bladder cancer: Long noncoding RNAs are on the stage. Mol Cancer. 12:1012013. View Article : Google Scholar : PubMed/NCBI
27	Chen J, Miao Z, Xue B, Shan Y, Weng G and Shen B: Long non-coding RNAs in urologic malignancies: Functional roles and clinical translation. J Cancer. 28:1842–1855. 2016. View Article : Google Scholar
28	Li LJ, Zhu JL, Bao WS, Chen DK, Huang WW and Weng ZL: Long noncoding RNA GHET1 promotes the development of bladder cancer. Int J Clin Exp Pathol. 7:7196–7205. 2014.PubMed/NCBI
29	Wang HM, Lu JH, Chen WY and Gu AQ: Upregulated lncRNA-UCA1 contributes to progression of lung cancer and is closely related to clinical diagnosis as a predictive biomarker in plasma. Int J Clin Exp Med. 8:11824–11830. 2015.PubMed/NCBI
30	Zhu YP, Bian XJ, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL and Shen YJ: Long noncoding RNA expression signatures of bladder cancer revealed by microarray. Oncol Lett. 7:1197–1202. 2014. View Article : Google Scholar : PubMed/NCBI
31	Zhao XL, Zhao ZH, Xu WC, Hou JQ and Du XY: Increased expression of SPRY4-IT1 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer. Int J Clin Exp Pathol. 8:1954–1960. 2015.PubMed/NCBI
32	Yan TH, Lu SW, Huang YQ, Que GB, Chen JH, Chen YP, Zhang HB, Liang XL and Jiang JH: Upregulation of the long noncoding RNA HOTAIR predicts recurrence in stage Ta/T1 bladder cancer. Tumour Biol. 35:10249–10257. 2014. View Article : Google Scholar : PubMed/NCBI
33	Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F and Liu Y: TGF-β-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. Clin Cancer Res. 20:1531–1541. 2014. View Article : Google Scholar : PubMed/NCBI
34	Zhou Y, Zhang X and Klibanski A: MEG3 noncoding RNA: A tumor suppressor. J Mol Endocrinol. 48:R45–R53. 2012. View Article : Google Scholar : PubMed/NCBI